Solid Biosciences Inc. entered into a securities purchase agreement with certain institutional accredited investors to issue common stock and Pre-Funded warrants for a aggregate proceeds of $108,858,550.452 on January 8, 2024. The company will issue 16,973,103 shares of the Company?s common stock, par value $0.001 per share, at a price of $5.53 per share for a gross proceeds $93,861,259.59, and to one Investor in lieu of Shares, pre-funded warrants to purchase 2,712,478 shares of the Company?s common stock, at a price of $5.529 per pre-funded Warrant for a gross proceeds $14,997,290.862. The transaction included participation from returning investors, Perceptive Advisors LLC , Adage Capital Partners LP a fund managed by a fund managed by, Deerfield Management Company, Invus, Janus Henderson Investors, Vestal Point Capital, LP, Bain Capital Life Sciences a fund managed by Bain Capital Private Equity, LP, RA Capital Management and an undisclosed life sciences investor, among others.

The Private Placement is expected to close on or about January 11, 2024, subject to the satisfaction of certain customary closing conditions. The Company has granted the Investors indemnification rights with respect to its representations, warranties, covenants and agreements under the Securities Purchase Agreement. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until exercised in full.